Research

Shamanic Medicine — From Ancient Rituals to Modern Science

For 10,000 years, shamanic cultures have used plant medicines to heal the mind. Now, the world's leading research institutions are validating what indigenous peoples always knew — and navigating the complex ethics of who owns that knowledge.

$6.9B

Projected Psychedelic Therapy Market (2030)

Data Bridge Market Research 2024

130+

Active Clinical Trials

ClinicalTrials.gov as of 2024

FDA Breakthrough Therapy Designations

Psilocybin (×2) + MDMA

10,000+

Years of Documented Use

Psilocybin mushroom stone artifacts, Guatemala

What Is Shamanic Medicine?

Shamanic medicine refers to the use of psychoactive plants and substances within traditional healing contexts — guided by a shaman, curandero, or medicine keeper who mediates between the human and spirit worlds. For millennia, these practices were inseparable from their cultural contexts: the Mazatec velada (mushroom ceremony), the Shipibo ayahuasca ritual, the Bwiti iboga initiation, the Huichol peyote pilgrimage.

The modern era has split this tradition into two streams. The first is psychedelic-assisted therapy — clinical, medicalized, stripped of cultural context, and increasingly backed by rigorous science. The second is the global retreat industry — a $12 billion wellness sector that ranges from authentic indigenous ceremony to luxury jungle lodges to weekend mushroom workshops in Amsterdam. Both streams raise the same question: can the medicine be separated from its cultural container without losing its essence?

The mushroom speaks, and our opinions rest on its authority.

— Terence McKenna

The Big Five — Major Shamanic Medicines

Five substances dominate the intersection of traditional shamanic use and modern clinical research. Each has a distinct cultural lineage, pharmacological mechanism, and regulatory trajectory.

Origin: Amazonian basin (Shipibo, Quechua, Ashaninka peoples). Active compound: N,N-DMT from Psychotria viridis, potentiated by MAO inhibitors in Banisteriopsis caapi. Mechanism: 5-HT2A agonist with sigma-1 receptor activity. Duration: 4-6 hours. Clinical status: Phase II trials for treatment-resistant depression (University of Sao Paulo). MAPS and Beckley Foundation funding large-scale studies. Key finding: Palhano-Fontes et al. (2019) showed significant antidepressant effects in a randomized placebo-controlled trial (n=29). 64% of patients achieved remission at 7-day follow-up.

Origin: Mesoamerica (Mazatec, Aztec). Over 200 species of psilocybin-producing mushrooms worldwide. Active compound: Psilocybin (prodrug) → Psilocin (active). Mechanism: 5-HT2A agonist; increases neural connectivity and disrupts the Default Mode Network (DMN). Duration: 4-6 hours. Clinical status: TWO FDA Breakthrough Therapy designations — for treatment-resistant depression (Compass Pathways, 2018) and major depressive disorder (Usona Institute, 2019). Johns Hopkins (2020): 71% of participants with major depression showed clinically significant response at 4 weeks; 54% in remission. The most advanced psychedelic in clinical development.

Origin: Central-West Africa (Bwiti tradition, Gabon). Active compound: Ibogaine from Tabernanthe iboga. Mechanism: Multi-target — NMDA antagonist, kappa opioid agonist, sigma-2 agonist, serotonin transporter inhibitor. Uniquely "resets" opioid receptor sensitivity. Duration: 24-36 hours (peak 4-8 hours). Clinical status: No FDA trials due to cardiac risks (QT prolongation). Observational studies in Mexico and New Zealand show 50-80% reduction in opioid use at 12-month follow-up. MAPS funded a safety study. DemeRx developing non-cardiotoxic analogue 18-MC (Phase I/II).

Origin: Mesoamerica and North American southwest (Huichol, Navajo, Native American Church). Active compound: Mescaline (3,4,5-trimethoxyphenethylamine). Mechanism: 5-HT2A/2C agonist with unique phenomenology — more visual, less introspective than psilocybin. Duration: 8-12 hours. Clinical status: Almost no modern clinical research due to cultural sensitivity and slow growth (10-15 years to maturity). University of Alabama at Birmingham conducting first modern study on mescaline's effects on mental health (observational, 2022-present). Synthetic mescaline research may bypass supply issues.

Origin: Sonoran Desert toad (Bufo alvarius) secretion; also found in several plant species. Active compound: 5-methoxy-N,N-dimethyltryptamine. Mechanism: 5-HT1A/2A agonist. Described as the most intense psychedelic experience known — complete ego dissolution in seconds. Duration: 15-30 minutes. Clinical status: Johns Hopkins (2019) survey of 362 users: 80% reported improvements in anxiety/depression. Phase I trial by Beckley Psytech for treatment-resistant depression completed 2023. Usona Institute also investigating. Growing consensus that synthetic 5-MeO-DMT should replace toad-derived to protect endangered populations.

The FDA does not approve molecules. It approves treatments.

Plant Medicine Map — Substance, Status, Science

Substance	Origin	Compound	US	EU	Japan	Trials
Ayahuasca	Amazon	DMT + MAOi	Illegal (Schedule I)	Varies (NL courts: legal)	Illegal	Phase II
Psilocybin	Global (200+ spp.)	Psilocybin → Psilocin	Schedule I (OR/CO exempt)	NL: fresh truffles legal	Illegal	Phase II/III
Ibogaine	Central-West Africa	Ibogaine	Schedule I	Unregulated (most)	Not scheduled	Observational
Mescaline	Mesoamerica	Mescaline	Schedule I (NAC exempt)	Illegal (most)	Illegal	Observational
5-MeO-DMT	Sonoran Desert	5-MeO-DMT	Schedule I	Varies	Illegal	Phase I
MDMA	Synthetic (1912)	MDMA	Schedule I	Illegal	Illegal	Phase III (PTSD)
Ketamine	Synthetic (1962)	Ketamine / Esketamine	Legal (Rx)	Legal (Rx)	Legal (Rx)	Approved (Spravato)

Clinical Research — The Three Pillars

Three institutions have driven the modern psychedelic research renaissance. Together, they have produced the evidence base that has led to FDA Breakthrough Therapy designations, the first legal psychedelic therapy programs, and a fundamental shift in how psychiatry views consciousness.

71%

Depression Response (Psilocybin)

Johns Hopkins 2020, 4-week follow-up

67%

PTSD Remission (MDMA)

MAPS MAPP1, 18-week follow-up

80%

Smoking Cessation (Psilocybin)

JHU 6-month vs ~35% standard care

Founded 2019 with $17M in private funding. Landmark study (2020): psilocybin for major depression — 71% showed clinically significant response at 4 weeks, 54% remission. Also investigating psilocybin for anorexia, Alzheimer's disease-related distress, opioid use disorder, PTSD, and tobacco addiction (80% abstinence at 6 months vs ~35% for best existing therapy). Lead researcher: Roland Griffiths (1946-2023), who published the field-defining 2006 study on mystical experiences induced by psilocybin.

Founded 1986 by Rick Doblin. Conducted the only completed Phase III trials for psychedelic-assisted therapy (MDMA for PTSD). MAPP1 (2021): 67% of participants no longer met PTSD criteria at 18 weeks (vs 32% placebo). MAPP2 confirmed results. However, FDA advisory committee voted 9-2 against approval in June 2024, citing concerns about blinding, study conduct, and integration of therapy with drug effects. Lykos Therapeutics (MAPS's for-profit spinoff) continues to seek approval pathway. This setback highlights the regulatory complexity of psychedelic-assisted therapy, where the therapy itself — not just the molecule — is the treatment.

Led by Robin Carhart-Harris, who developed the Entropic Brain Hypothesis: psychedelics increase neural entropy (disorder), temporarily dissolving the Default Mode Network and enabling new patterns of brain connectivity. Key studies: First modern neuroimaging of psilocybin (2012), first modern clinical trial for depression (2016), psilocybin vs escitalopram comparison (2021) — psilocybin showed comparable efficacy with fewer side effects. Also conducted the landmark self-blinding microdose study (2021, n=191) showing no significant difference from placebo.

Microdosing — What the Science Actually Says

Microdosing — sub-perceptual doses of psychedelics taken on a schedule (typically every 3 days) — has become a cultural phenomenon. Tens of thousands participate in online communities (r/microdosing: 200,000+ members). Reported benefits include enhanced creativity, focus, emotional regulation, and reduced anxiety.

However, the most rigorous science tells a more nuanced story. The Imperial College London self-blinding study (Szigeti et al., 2021) — the largest placebo-controlled microdosing study to date — found that while participants who believed they were microdosing showed significant improvements, there was no significant difference between the microdose and placebo groups. A 2022 meta-analysis in the Journal of Psychopharmacology confirmed: across all controlled studies, microdosing effects on mood and cognition are "not reliably distinguishable from placebo."

The Ritual Hypothesis

If microdosing works through expectation and ritual rather than pharmacology, this paradoxically validates the SBNR framework: intentionality, ceremony, and belief structure may be the active ingredients. The medicine is the practice, not the molecule. This aligns with indigenous perspectives that have always emphasized set, setting, and intention over dose.

Legal Landscape — A World in Transition

The global legal landscape for psychedelic substances is shifting faster than at any point since the Controlled Substances Act of 1970. In 2019, Denver became the first US city to decriminalize psilocybin. By 2024, Oregon has legal psilocybin therapy, Colorado has decriminalized five psychedelics, and Australia allows prescription psilocybin and MDMA.

Region	Status	Details
Oregon (US)	Legal (supervised)	Measure 109 (2020): First US jurisdiction to legalize psilocybin-assisted therapy. Licensed service centers opened January 2023. Sessions cost $1,500-$3,500. No diagnosis required.
Colorado (US)	Decriminalized	Proposition 122 (2022): Decriminalized psilocybin, psilocin, DMT, ibogaine, and mescaline (excluding peyote). Licensed healing centers planned for 2025.
Netherlands	Partially Legal	Dried magic mushrooms banned in 2008 after tourist death. However, psilocybin truffles (sclerotia) remain legal through a loophole — sold openly in smart shops. Retreat industry thrives.
Jamaica	Legal (no law)	Psilocybin mushrooms were never scheduled. High-end psilocybin retreats (MycoMeditations, Atman Retreat) serve international clientele at $2,500-$7,500/week.
Brazil	Legal (ayahuasca)	Ayahuasca legal for religious use (Santo Daime, UDV) since 2006. Therapeutic retreats operate in a gray area. National Council on Drug Policy issued supportive framework.
Australia	Legal (Rx)	TGA rescheduled psilocybin and MDMA in July 2023 — first country to allow prescription psychedelic therapy. Authorized psychiatrists only. Limited uptake due to cost ($25,000+ per treatment course).
Japan	Strictly Illegal	Psilocybin, DMT, mescaline, and MDMA are all controlled substances. No clinical trials, no decriminalization movement, no religious exemptions. Japan remains one of the strictest jurisdictions globally for psychedelic substances.

We do not own the medicine. The medicine owns itself.

— Bwiti teaching

Safety & Risks

Psychedelic substances carry real medical risks — particularly in unregulated settings where screening, supervision, and integration support are absent. The following are the most critical safety considerations.

Ayahuasca's MAO-inhibiting properties create dangerous interactions with SSRIs, SNRIs, and other serotonergic medications. Symptoms: hyperthermia, agitation, rigidity, seizures. Can be fatal. A minimum 2-6 week washout period from SSRIs is required before ayahuasca use — yet many retreat centers fail to screen adequately.

Ibogaine prolongs the QT interval, creating risk of Torsades de Pointes and sudden cardiac death. At least 30 deaths have been reported in clinical and ceremonial settings. Pre-screening with 12-lead ECG and cardiac history is essential but not universally practiced.

Psychedelics can precipitate psychotic episodes in individuals with predisposition to schizophrenia or bipolar disorder. Even in healthy individuals, "bad trips" can cause lasting PTSD-like symptoms if not properly supported. Set (mindset), setting (environment), and integration (post-experience therapy) are as important as the substance itself.

Across all psychedelics: personal or family history of psychotic disorders, lithium use (seizure risk with psilocybin), MAOIs + serotonergic drugs (ayahuasca), heart conditions (ibogaine), pregnancy. The unregulated nature of most retreat settings means these contraindications are not always screened.

Cultural Respect & Indigenous IP

The psychedelic renaissance raises urgent questions about cultural appropriation, benefit-sharing, and indigenous intellectual property. When a pharmaceutical company patents a psilocybin formulation based on knowledge that Mazatec peoples have held for millennia, who benefits?

Reciprocal Cacao Agreement (2023)

A landmark framework establishing benefit-sharing between Western companies and Mesoamerican cacao-producing communities. Cited as a model for psychedelic benefit-sharing. Requires 1-5% of revenue to flow back to indigenous source communities.

Nagoya Protocol (2010)

International treaty under the Convention on Biological Diversity requiring "access and benefit-sharing" (ABS) for genetic resources and traditional knowledge. Ratified by 137 countries. However, enforcement is weak — no psychedelic patent has been successfully challenged under the Nagoya Protocol to date.

The Compass Pathways Controversy

Compass Pathways (backed by Peter Thiel) holds patents on psilocybin therapy methods that many researchers and advocates argue should be common knowledge. The company's aggressive patent strategy — including patents on room design and therapist hand-holding — has drawn sharp criticism from the psychedelic community and raised questions about whether corporate interests are compatible with the medicine's cultural origins.

Sources & Further Reading

Davis, A. K. et al. (2021). Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry.
Mitchell, J. M. et al. (2021). MDMA-assisted therapy for severe PTSD. Nature Medicine.
Palhano-Fontes, F. et al. (2019). Rapid antidepressant effects of ayahuasca. Psychological Medicine.
Carhart-Harris, R. L. et al. (2021). Trial of psilocybin versus escitalopram for depression. NEJM.
Szigeti, B. et al. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife.
Griffiths, R. R. et al. (2006). Psilocybin can occasion mystical-type experiences. Psychopharmacology.
Noller, G. E. et al. (2018). Ibogaine treatment outcomes for opioid dependence. Am J Drug Alcohol Abuse.
FDA Advisory Committee (2024). MDMA Capsules for PTSD — Briefing Document.
Data Bridge Market Research (2024). Global Psychedelic Therapeutics Market Report.
Nagoya Protocol on Access and Benefit-Sharing (2010). Convention on Biological Diversity.

← Back to Research